Beryl Drugs

Beryl Drugs EBITDA per Share

The EBITDA per Share of Beryl Drugs (524606.BO) as of Oct 23, 2026 is 1.98 INR. In the previous year, EBITDA per Share was 2.41 INR — a change of -18.13% (lower).

EBITDA per Share

1.98INR

YoY

-18.13%

Last updated:

EBITDA per Share of Beryl Drugs is 2026 1.98 INR. EBITDA per Share of Beryl Drugs was 2025 2.41 INR. It decreases by -18.13% lower compared to the previous year.

The Beryl Drugs EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.46 INR
Jan 1, 2019
1.44 INR
Jan 1, 2021
0.38 INR
Jan 1, 2022
0.82 INR
Jan 1, 2023
3.81 INR
Jan 1, 2024
4.47 INR
Jan 1, 2025
2.41 INR
Jan 1, 2026
1.98 INR
The Beryl Drugs EBITDA per Share history
YEAREBITDA per ShareYoY
1.98INR-18.13%
2.41INR-46.03%
4.47INR+17.40%
3.81INR+365.55%
0.82INR+115.52%
0.38INR-73.65%
1.44INR-1.00%
1.46INR+99.00%
0.73INR+72.20%
0.42INR-30.67%
0.61INR-38.93%
1.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Beryl Drugs Stock analysis

What does Beryl Drugs do? Beryl Drugs Ltd. manufactures bulk drugs and offers small volume injectables in liquid and dry powder forms, eye and ear drops, intravenous fluids in poly packs and glass bottles, and veterinary medicines. The company supplies domestically, institutionally, and for export, leveraging its Pithampur manufacturing facility. It markets branded and generic pharmaceutical formulations through its nationwide sales and distribution network. The firm's revenue streams come from the sale of bulk drugs to pharmaceutical manufacturers and the distribution of branded and generic formulations to domestic and international markets. Institutional buyers include hospitals and healthcare providers, while export markets receive bulk drug supplies and veterinary medicines. Domestic sales focus on retail pharmacies and healthcare institutions. Beryl Drugs Ltd. serves the pharmaceutical industry by providing bulk drug manufacturing services and branded generic formulations. Its products are distributed through a nationwide network, targeting both institutional and retail segments. The company's export segment includes veterinary medicines and bulk drug supplies to international clients. Beryl Drugs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beryl Drugs stock

EBITDA per Share of Beryl Drugs is 1.98 INR in 2026.

EBITDA per Share of Beryl Drugs changed from 2.41 INR to 1.98 INR, representing a -18.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Beryl Drugs since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Beryl Drugs

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Beryl Drugs